Avinash Chandra
Cardiovascular Disease · Newark, DENPI 1013190651
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $5,376 of the $7,971 with a category attached, or 67.4%. 14 manufacturers reported payments, led by Abbott at 55.1% of the total. 2025 is the largest year on record at $6,278, more than ten times the $274 reported in 2019.
Across 80 payments — averaging $99.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Edwards Lifesciences$3K
- Novartis$202
- Johnson & Johnson$75
- Abiomed$46
- E.r. Squibb & Sons, L.L.C.$39
- plus $168 from 8 others
What the payments were for
- Travel & lodging$5,37667%
- Food & beverage$2,59533%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 30 | $4,395 |
| Edwards Lifesciences | 16 | $3,045 |
| Novartis | 14 | $202 |
| Johnson & Johnson | 5 | $75 |
| Abiomed | 1 | $46 |
| E.r. Squibb & Sons, L.L.C. | 3 | $39 |
| AstraZeneca | 2 | $37 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $30 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $20 |
| Lantheus Medical Imaging, Inc. | 1 | $19 |
| Amgen | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $16 |
| Amarin Pharma, Inc. | 1 | $15 |
| Pfizer | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,971 in reported general payments places this provider in the 70th percentile of 104 cardiovascular disease providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 267 | $411,874 |
| XareltoRivaroxaban | 80 | $112,672 |
| EntrestoSacubitril/Valsartan | 33 | $39,969 |
| FarxigaDapagliflozin Propanediol | 27 | $32,325 |
| BrilintaTicagrelor | 30 | $30,174 |
| JardianceEmpagliflozin | 19 | $28,722 |
| Repatha SureclickEvolocumab | 25 | $24,471 |
| Praluent PenAlirocumab | 12 | $15,543 |
| Atorvastatin Calcium | 521 | $9,178 |
| Metoprolol Succinate | 375 | $6,385 |
| Rosuvastatin Calcium | 252 | $5,947 |
| Ezetimibe | 102 | $4,003 |
| Amlodipine Besylate | 328 | $3,384 |
| Valsartan | 98 | $2,744 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 42 | $2,478 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $411,874267 claims |
| Johnson & JohnsonXarelto | $75 | $112,67280 claims |
| AstraZenecaFarxiga, Brilinta | $37 | $62,49957 claims |
| NovartisEntresto | $202 | $39,96933 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 104 cardiovascular disease providers in Delaware.
Other cardiovascular disease in Newark
- Edward GoldenbergNewark$52K
- Muhammad ShakirNewark$47K
- Anthony AlfieriNewark$45K
- Sean DikdanNewark$42K
- Kirk GarrattNewark$38K
- Anthony ClayNewark$37K
- Ashish ParikhNewark$26K
- William WeintraubNewark$24K
- Wen Chi TsaiNewark$20K
- Stephen MengNewark$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.